Meningococcal Polysaccharide Vaccine Groups->aspalthic products

Join

Help

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Meningococcal Polysaccharide Vaccine Groups

Category :

Chemicals->Chemical->aspalthic products

Meningococcal Polysaccharide Vaccine Groups

Product Specification

Model No:	0.5ml/vial

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

Product Detail

ACYW135 Meningococcal Polysaccharide Vaccine


 
[Eligibles] 
Adults and children over two years of age. 
[Function and use] 
The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135. 
[Description] 
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution. 
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides. 
Subsidiary materials: All the components of subsidiary materials approved shall be listed. 
Vaccine diluent: Sterile, pyrogen-free PBS. 
[Specifications] 
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135). 
[Feature] 
Fill a gap in our country for the first time by developing 4-valent vaccine . 
Improve traditional purification technology to eliminate nucleic acid and protein. 
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards. 
[Advantages] 
(1)Apply modern biotechnology to purification involved in manufacture and best technology process for culture preparation; 
(2)Apply automatic fermentation system for bacterial culture to whole production process; 
(3)High purity vaccine with high quality indexes; 
(4)High-level immunogenicity, high GMT level of conversion rate of antibody PT, FHA, T and D in serum, providing ideal protection and prevention; 
(5)One dose for immunization to prevent infection of four meningococcal; 
(6)Lyophilized dosage form for quality guarantee; 
(7)Large annual production capability to meet the demands of different groups for the prevention of meningococcal disease. 
<div>
 
</div>
 
1.Group ACYW135                              
2.Group A+C                                       
3.prevent epidemic cerebrospinal meningitis                                                   


4.purified capsular polysaccharide antigens  
<img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /> 
 



 
ccls-vaccine.com

More Products from this Supplier

Medical hepatitis A vaccine

Medical Inactivated Influenza Vaccine

Split Influenza Vaccine For Human

Lyophilized varicella vaccine, live


[ Back Products Catalog ]

Commerce Member:
Please log in your ID and password, we will later fill in relating info.

ID:

Password:

Remember my ID on this computer


	Complete this form below to send out your enquiries. All enquiries will be automatically sent to the company you want to develop.

	Subject
	Content	(Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)

Company Profile:

* Company Name

*E-mail

*Country

*Contact Person

URL

*Phone

- -

Fax

- -

*Postal code

*City

*Street Address

*Business Nature

Distributor Exporter Importer Manufacturer
Whole Sale Retailer Reseller Retrofitter User
Others, please specify:

*Security Code


Enter the security code.